ALMS

Rating neutralTentativeAI MemoPost-earnings T+3

Alumis

As of 2026-08-24/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-24 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Q2 2026 print: clinical progress but weak financial optics • 2026-08-13

Base target: $27 / p=45% prob

Biggest risk

The post-print setup is less constructive: the quarter showed minimal collaboration revenue, a large net loss, a lonigutamab impairment, and no product revenue. Post-print analyst reaction was mixed: HC Wainwright reiterated Neutral with a $25 target on August 14 and Citi reiterated Neutral on August 17, while other firms maintained Buy ratings and targets including $39 from Morgan Stanley and $55 from Oppenheimer. Price action was weak through August 20 before rebounding, suggesting the market has not fully resolved financial and execution concerns.

Invalidation

Break below $17 or thesis failure.

What would change my mind?

The primary Q2 update combines strong psoriasis durability data, a Q3 SLE readout, a Q4 psoriasis NDA target, and cash runway stated through Q4 2027 [#SEC-8K-2026-08-13]. These milestones could support a materially higher valuation if SLE broadens the franchise and the NDA remains on schedule.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-08-24

Base target

$27

p=45%

Bull target

$40

p=25%

Bear target

$17

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

TYK2 franchise expansion
The primary Q2 update combines strong psoriasis durability data, a Q3 SLE readout, a Q4 psoriasis NDA target, and cash runway stated through Q4 2027 [#SEC-8K-2026-08-13].
These milestones could support a materially higher valuation if SLE broadens the franchise and the NDA remains on schedule.

BearKey bullets

Cash runway depends on management’s operating plan; continued development spending could increase financing risk if milestones slip.
FDA review, NDA timing, or approval could be delayed or produce an unfavorable label.
Negative or ambiguous LUMUS SLE data could materially reduce the perceived TYK2 franchise opportunity.

WatchKey bullets

Q2 2026 print: clinical progress but weak financial optics

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $27 (p=45%)

Target spread vs base: +48% / -37%

Scenario probabilities

Bull Target: $40 (p=25%)Base Target: $27 (p=45%)Bear Target: $17 (p=30%)

Commentary

Post-earnings tone is mixed rather than decisively bullish. The primary release is constructive on psoriasis efficacy, cash runway, LUMUS timing, and the NDA plan [#SEC-8K-2026-08-13], but the financial print and lonigutamab impairment weigh on sentiment. Secondary price history showed closes of $24.41 on August 13 (-4.46%), $23.99 on August 19 (-3.58%), and $22.86 on August 20 (-4.71%), followed by $24.17 on August 21 (+5.73%). Analyst revisions are available but mixed, with neutral reiterations alongside maintained buy targets. The deterministic prior remains negative across 5-day to 120-day horizons, supporting monitoring rather than chasing strength.

As of 2026-08-24 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

TYK2 franchise expansion

Scenarios

Bull Target (Scenario probability)

$40 / p=25% prob

Base Target (Scenario probability)

$27 / p=45% prob

Bear Target (Scenario probability)

$17 / p=30% prob

Analysis 2026-08-24 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-08-13
Q2 2026 print: clinical progress but weak financial optics
The company reported 54% PASI 100 at 48 weeks, $502.3 million in cash and marketable securities, and runway into Q4 2027, but also $1.662 million of revenue, a $142.2 million net loss, and a $41.8 million lonigutamab impairment [#SEC-8K-2026-08-13]. Secondary market data reported EPS of -$1.11 versus approximately -$0.77 consensus; treat the comparison cautiously because consensus is not in the primary release.
Prob 100.00% • Move -5.70% • Priced-in 100.00%
EVENT2026-11-22
Potentially pivotal LUMUS SLE topline data
Alumis anticipates Phase 2b LUMUS topline data in systemic lupus erythematosus during Q3 2026. A positive readout could broaden the TYK2 opportunity, while a miss would expose the stock to substantial binary downside [#SEC-8K-2026-08-13].
Prob 60.00% • Move 28.00% • Priced-in 35.00%
EVENT2026-11-22
Psoriasis NDA submission
Management remains on track to submit an FDA NDA for envudeucitinib in moderate-to-severe plaque psoriasis in Q4 2026 [#SEC-8K-2026-08-13].
Prob 75.00% • Move 15.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

TYK2 franchise expansion
2027-08-24
Sjögren’s disease and cutaneous lupus erythematosus are prioritized contingent on LUMUS results and capital allocation, while an A-005 Parkinson’s Phase 2 biomarker trial is planned for the first half of 2027 [#SEC-8K-2026-08-13].
Prob 45% • Move 20% • Priced-in 20%

Risks

Cash runway depends on management’s operating plan; continued development spending could increase financing risk if milestones slip.
FDA review, NDA timing, or approval could be delayed or produce an unfavorable label.
Negative or ambiguous LUMUS SLE data could materially reduce the perceived TYK2 franchise opportunity.
The company remains pre-commercial with very limited collaboration revenue and substantial operating losses.
The lonigutamab strategic review and impairment indicate portfolio-prioritization and execution risk.
The scheduled T3 packet labels August 19 as the earnings date, while the company’s IR and SEC materials identify the Q2 release on August 13, creating a timing-data caveat.

Peers

Symbol	Summary
ARQT	Closest available dermatology-biotech comparator by indication framing and market capitalization, though the packet provides no fresh relative valuation data.
CLDX	Same-sector, similar-cap clinical biotech candidate; useful for framing binary development risk but not a close operating match.
IOVA	Same-sector, similar-cap clinical biotech candidate; a loose comparator for trial execution, financing, and commercialization risk.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-24

Loading AI feed…

Symbol

Summary

ARQT

Closest available dermatology-biotech comparator by indication framing and market capitalization, though the packet provides no fresh relative valuation data.

CLDX

Same-sector, similar-cap clinical biotech candidate; useful for framing binary development risk but not a close operating match.

IOVA

Same-sector, similar-cap clinical biotech candidate; a loose comparator for trial execution, financing, and commercialization risk.